Literature DB >> 3130690

Immunity after treatment of human schistosomiasis mansoni quantitative and qualitative antibody responses to tegumental membrane antigens prepared from adult worms.

S M Roberts1, R A Wilson, J H Ouma, H C Kariuki, D Koech, T K arap Siongok, R F Sturrock, A E Butterworth.   

Abstract

Quantitative antibody responses of individual Kenyan children to a tegument membrane preparation from adult schistosomes have been studied by enzyme-linked immunosorbent assay. Qualitative differences between patients were examined by electrophoretic fractionation of the membrane preparation followed by Western blotting analysis. All individuals had antibodies to the preparation, the level increasing twofold shortly after chemotherapy and declining to pre-treatment levels by 6 months. Susceptible children had significantly higher levels of antibody than resistant individuals at 12 and 18 months after chemotherapy. Antibody levels were positively associated with patient age (particularly over the range 8-12 years at the first bleed after chemotherapy) and the logarithm of pre-treatment egg excretion. The strongest association was observed between initial antibody level and subsequent levels. A total of 47 distinct antigens was detected in the membrane preparation. The major antigens were detected equally strongly by sera from both susceptible and resistant groups of children. At the outset the resistant group responded more strongly to 35%, and more weakly to 15%, of the antigens than the susceptible group. At the end of the study the figures were reversed, being 21% and 38% respectively, probably reflecting the reflecting the reinfection of the susceptible group. 3 antigens of molecular mass 100, 50 and 27 kDa were exceptions to the trend, being detected more strongly by the resistant than the susceptible group at one or more later times. It was concluded that the differences in total antibody level to the tegument membrane preparation were insufficient to account for the resistant or susceptible status of the children.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3130690     DOI: 10.1016/0035-9203(87)90034-4

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  3 in total

1.  Previous or ongoing schistosome infections do not compromise the efficacy of the attenuated cercaria vaccine.

Authors:  Thomas M Kariuki; Govert J Van Dam; André M Deelder; Idle O Farah; Dorcas S Yole; R Alan Wilson; Patricia S Coulson
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Epitope Mapping of Exposed Tegument and Alimentary Tract Proteins Identifies Putative Antigenic Targets of the Attenuated Schistosome Vaccine.

Authors:  Leonardo P Farias; Gillian M Vance; Patricia S Coulson; Juliana Vitoriano-Souza; Almiro Pires da Silva Neto; Arporn Wangwiwatsin; Leandro Xavier Neves; William Castro-Borges; Stuart McNicholas; Keith S Wilson; Luciana C C Leite; R Alan Wilson
Journal:  Front Immunol       Date:  2021-03-03       Impact factor: 7.561

3.  Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial.

Authors:  Robert Tweyongyere; Patrice A Mawa; Nicholas O Emojong; Harriet Mpairwe; Frances M Jones; Trinh Duong; David W Dunne; Birgitte J Vennervald; Eli Katunguka-Rwakishaya; Alison M Elliott
Journal:  BMC Infect Dis       Date:  2009-03-18       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.